Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Share-based Compensation (2020 - 2025)

RxSight (RXST) has disclosed Share-based Compensation for 6 consecutive years, with $7.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 7.35% year-over-year to $7.8 million, compared with a TTM value of $31.6 million through Dec 2025, up 28.32%, and an annual FY2025 reading of $31.6 million, up 28.32% over the prior year.
  • Share-based Compensation was $7.8 million for Q4 2025 at RxSight, down from $8.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $8.5 million in Q2 2025 and bottomed at $1.2 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $4.5 million, with a median of $4.0 million recorded in 2023.
  • The sharpest move saw Share-based Compensation skyrocketed 135.81% in 2021, then increased 1.54% in 2022.
  • Year by year, Share-based Compensation stood at $2.9 million in 2021, then rose by 1.54% to $3.0 million in 2022, then soared by 49.39% to $4.4 million in 2023, then soared by 64.56% to $7.3 million in 2024, then rose by 7.35% to $7.8 million in 2025.
  • Business Quant data shows Share-based Compensation for RXST at $7.8 million in Q4 2025, $8.1 million in Q3 2025, and $8.5 million in Q2 2025.